MicroRNAs in melanoma development and resistance to target therapy by Fattore, Luigi et al.
Oncotarget22262www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 13), pp: 22262-22278
MicroRNAs in melanoma development and resistance to target 
therapy
Luigi Fattore1, Susan Costantini2, Debora Malpicci3, Ciro Francesco Ruggiero3, 
Paolo Antonio Ascierto1, Carlo M. Croce4, Rita Mancini5 and Gennaro Ciliberto1,6
1 Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale”, Naples, Italy
2 CROM, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, Naples, Italy
3 Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Catanzaro “Magna Graecia”, Catanzaro, Italy
4 Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University Comprehensive Cancer 
Center, Columbus, OH, USA
5 Dipartimento di Medicina Clinica e Molecolare, Sapienza Università di Roma, Rome, Italy
6 IRCCS Istituto Nazionale Tumori “Regina Elena”, Rome, Italy
Correspondence to: Gennaro Ciliberto, email: gennaro.ciliberto@ifo.gov.it
Keywords: melanoma, miRNA, target therapy, drug resistance, intracellular pathways
Received: August 04, 2016 Accepted: January 10, 2017 Published: January 19, 2017
ABSTRACT
microRNAs constitute a complex class of pleiotropic post-transcriptional 
regulators of gene expression involved in the control of several physiologic and 
pathologic processes. Their mechanism of action is primarily based on the imperfect 
matching of a seed region located at the 5’ end of a 21-23 nt sequence with a partially 
complementary sequence located in the 3’ untranslated region of target mRNAs. This 
leads to inhibition of mRNA translation and eventually to its degradation. Individual 
miRNAs are capable of binding to several mRNAs and several miRNAs are capable 
of influencing the function of the same mRNAs. In recent years networks of miRNAs 
are emerging as capable of controlling key signaling pathways responsible for the 
growth and propagation of cancer cells. Furthermore several examples have been 
provided which highlight the involvement of miRNAs in the development of resistance 
to targeted drug therapies. In this review we provide an updated overview of the 
role of miRNAs in the development of melanoma and the identification of the main 
downstream pathways controlled by these miRNAs. Furthermore we discuss a group 
of miRNAs capable to influence through their respective up- or down-modulation the 
development of resistance to BRAF and MEK inhibitors.
INTRODUCTION
Malignant melanoma is a neoplasm of melanocytes 
and its incidence has increased dramatically over the 
past few decades [1]. Surgery is still the main and 
definitive treatment for early-stage melanoma, but it is 
rarely curative for the advanced stages of melanomas 
[1]. Chemotherapy represents the past for the treatment 
of metastatic melanoma and it was based on 2 FDA-
approved drugs: fotemustine, dacarbazine [2]. In recent 
years, however, advances in the use of immunotherapy 
and targeted therapy have revolutionized clinical history 
of this disease thanks to their ability to significantly 
enhance proportion and duration of objective responses 
and to provide extended prolongation of patients’ survival. 
Immunotherapy is mostly based on immune checkpoint 
inhibitors targeting CTLA4 and, more recently, PD1/PDL1 
interaction [3]. Targeted therapies with MAPK pathway 
kinase inhibitors (KIs) have been developed thanks to the 
discovery that BRAF and NRAS mutations are among the 
major oncogenic drivers of melanoma proliferation and 
survival [4].
Approximately 50% of patients harbor v-raf 
murine sarcoma viral oncogene homolog B1 (BRAF) 
V600 mutations [5]. In 90% of cases BRAF mutations 
change Valine 600 into glutamic acid (V600E) [5]. Less 
frequently substitution with other aminoacids (V600D, 
V600R) is observed [5]. BRAFV600 mutated oncogenes 
lead to the uncontrolled activation of the mitogen-
activated protein kinase (MAPK) signalling pathway 
Review
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and act as the main oncogenic drivers of melanoma 
progression and proliferation [6]. These evidences lead 
initially to the clinical development of BRAF inhibitors, 
such as vemurafenib and dabrafenib, which are selective 
inhibitors of BRAF-V600 mutated oncogenes and have 
been approved by FDA [7, 8]. BRAF inhibitors (BRAFi) 
are active only in melanoma cells bearing V600 BRAF 
mutations, where this kinase is present as constitutively 
active monomers. In contrast BRAFi exert a paradoxical 
tumor promoting effect in RAS mutated melanomas where 
they induce the allosteric activation of heterodimeric 
complexes formed by mutated and wild-type BRAF 
monomers [9]. Single-agent vemurafenib and dabrafenib 
demonstrated unprecedented objective responses and 
improvements in progression-free and overall survival in 
patients with metastatic melanoma bearing BRAF V600E 
mutation, as compared to old chemotherapy approaches 
[10]. However, the duration of response was limited in 
time and the median progression free-survival extended 
only to 6-8 months because of the development of drug 
resistance [11, 12].
Acquired resistance to BRAF inhibitors is usually 
characterized by reactivation of the MAPK pathway 
[13, 14]. Furthermore, the scenario is complicated by 
the paradoxical development of secondary skin tumors, 
which may arise from the BRAF inhibitors-induced 
activation of MAPK pathway in wild-type BRAF cells 
[15]. For these reasons more recently the gold standard 
of therapy for BRAF mutated melanoma has become 
the combinations of different BRAF inhibitors (such as 
vemurafenib, dabrafenib and very recently encorafenib) 
with MEK inhibitors (such as trametinib, cobimetinib or 
binimetinib) [16-20]. These combinations significantly 
increase the percentage of objective responses, prolong 
overall and progression-free survival compared to single-
agent therapies and mitigate the emergence of resistance. 
However, also dual inhibition inevitably fails in the long 
term in the majority of cases [21, 22].
Several studies have been directed to understand 
the molecular mechanisms of acquired resistance. 
The first studies conducted on acquired resistance to 
BRAFi monotherapy identified NRAS or KRAS de 
novo mutations, mutant BRAF V600E amplification 
or its alternative splicing, MEK1/MEK2 mutations or 
CDKN2A loss at the basis of resistance [21, 23-25]. All 
these molecular alterations converge in the reactivation 
of the MAPK pathway. Furthermore, Shi and colleagues, 
through an intensive DNA deep sequencing analysis of a 
large number of tumor samples from patients resistant to 
different BRAFi monotherapies, confirmed that mutations 
correlated to the MAPK pathway are evident in the 
majority of cases (70%) [26]. Genetic alterations were 
found also in the PI3K/PTEN/AKT signalling pathway 
in 22% of cases [26]. The scenario is complicated by the 
existence of concomitant genetic alterations in both core 
drug escape pathways in 18% of cases, which occur in 
the same tumor or among multiple tumors from the same 
patient [26]. A more recent study also investigated the 
mechanisms of acquired resistance to BRAF and MEK 
inhibitors [22]. The analysis by whole exome sequencing, 
conducted on melanoma tissues from 28 patients suffering 
of double-drug disease progression, identified in the 
majority of cases (about 68%) molecular alterations in 
the MAPK and PI3K/PTEN/AKT signaling pathways, 
as previously reported [26], i.e. same genetic alterations, 
which occur in the resistance to BRAFi monotherapies 
were evident also in the double-drug disease progression 
[22]. These studies taken together suggest that also hitting 
hard melanoma cells simultaneously with BRAFi+MEKi 
combinations does not prevent the activation of escape 
mechanisms leading eventually to the selection of 
resistant cells bearing activation of the same survival and 
proliferation pathways. The question then arises as to 
which are these escape mechanisms.
In our opinion the answer can be found in a 
better understanding of adaptive epigenetic and/or post-
transcriptional mechanisms of resistance. In a significant 
percent of cases of drug resistant melanomas (about 26%) 
no new mutations have been found [26, 27]. Recent studies 
showed that melanoma cells exposed to MAPK inhibitors 
undergo early adaptive responses, which help the 
emergence of drug resistant cells [28, 29]. We and others, 
for example, identified the rapid phosphorylation of the 
ErbB3 receptor and the activation of the downstream AKT 
pathway as a key event responsible for the development 
of resistance to targeted therapies in melanoma through 
the activation of a feedback autocrine survival loop 
involving increased production the ErbB3 ligand 
neuregulin1 (NRG1) [30, 31]. Moreover, we demonstrated 
that blocking ErbB3 activity with a combination of 
neutralizing antibodies not only abolished early adaptive 
responses, but also impaired the establishment of long-
term resistance [30, 32].
We believe that a variety of post-transcriptional 
adaptive changes orchestrate the development of drug 
resistance, which involve also non-coding RNAs. In this 
context since microRNAs are important multifunctional 
post-transcriptional modulators of gene expression, which 
play key-roles in various human cancers [33, 34] it is of 
utmost importance to analyze their involvement in drug 
resistance. Here we review the emerging role of miRNAs 
as key players in melanoma progression and development 
of resistance and discuss the potential diagnostic and 
therapeutic implications.
MICRORNAS AS MAJOR POST-
TRANSCRIPTIONAL MODULATORS OF 
GENE EXPRESSION
During the last two decades small non-coding RNAs 
have been described as the undisputed protagonists of 
the eukaryotic post-transcriptional machinery regulation 
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[35]. Among them microRNAs (miRNAs) have become 
the subject of the most intensive studies and nowadays 
thousands of papers have been published on this matter. 
Furthermore there are over 2500 known human miRNAs, 
which are recorded in various online available databases 
[36]. miRNAs are short RNA about 22 nucleotides long 
which were found to be the most expressed class of non-
coding RNAs in eukaryotic somatic tissues [33]. Their 
main function is the modulation of gene expression 
through mRNA silencing or degradation and usually 
miRNAs have pleiotropic effects because a single miRNA 
is potentially able to target simultaneously several 
mRNAs [36, 37]. This feature explains how miRNAs are 
such a powerful regulators of gene expression and the 
complexity and multitude of cellular pathways they can 
affect. miRNAs usually induce the block of translation 
and the following destabilization of the mRNA target 
through an imperfect binding to its 3’UTR [36]. The 5’end 
domain (position 2 to 8) of each miRNAs is responsible 
for the recognizing and is called “seed region” [38]. 
Mature miRNAs, which share identical sequences at 
nucleotides 2-8 are generally considered to belong to the 
same “miRNA family” [39]. Virtually all mRNAs have 
conserved or non-conserved miRNAs binding sites and are 
supposed to be under miRNA post-transcriptional control. 
Hence, the biogenesis and the regulation of miRNAs 
themselves are tightly regulated [39]. The locations of 
miRNA sequences are in various genomic contexts and 
they are all transcribed, capped and polyadenylated by 
RNA polymerase II in a long primary transcript, called pri-
miRNAs [36, 37]. This long transcript is processed into 
the nucleus by the Drosha/DGCR8 complex, which chops 
the pri-miRNAs generating the pre-miRNA 70 bp long 
[36, 37]. pre-miRNAs are exported into the cytosol where 
they are processed by the RNAse III Dicer endonuclease 
originating the mature miRNA duplex [36, 37]. The mature 
miRNA is ready to be loaded together with the Argonaute2 
and the transactivation-responsive RNA-binding proteins 
to form the RISC complex (RNA-induced silencing 
complex) [36, 37]. This complex removes and degrades 
the complementary strand and retains the fully functional 
miRNA. The perfect or imperfect binding complementary 
determines the mRNA fate; indeed in the first case it is 
degraded while in the second case it is inhibited in its 
translation [38].
miRNAs are classified as “intergenic” or “intronic” 
or on the basis of their genomic location and are mostly 
situated in clusters [40]. The first ones are transcribed from 
Figure 1: Oncogenic BRAF V600/MAPK signaling pathway and the most relevant miRNAs connected to its deregulation 
in metastatic melanoma [59, 70, 75, 76]. Arrows and blocking bars indicate respectively the positive or negative regulation of MAPK 
signaling on a sets of miRNAs. Blocking bars also indicate the repression of specific miRNA exerted on specific members of this signaling 
pathway.
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Group 1: miRNAs associated with early progression of melanoma by a miRNAome profiling approach and selected with at 
least three-fold up- or down- regulation [43]; Group 2:miRNAs deregulated in melanomas vs melanocytes by two different 
miRNAome profiling approaches and selected with FDR (false discovery rate) of 0% [44] and with at least three-fold up- or 
down-regulation [45], respectively; Group 3: miRNAs associated to melanoma by studies involving individual miRNAs 
[55-65]; Group 4: miRNAs regulated by oncogenic BRAF and selected with at least two-fold up- or down-regulation [70]. 
Underlined miRNAs have been validated by qRT-PCR. miRNAs in bold have potential diagnostic and/or prognostic values 
in melanoma based on literature data [77, 78]. miRNAs indicated with an asterisk (*) are in common by at least two groups.
Table 1: Most representative deregulated microRNAs in melanoma.
List of the commonly deregulated pathways related to targets of up-regulated and down-regulated miRNAs belonging to the 
groups 1-4, reported in Figure 2C and D.
Table 2: Common deregulated pathways related to up or down-regulated microRNAs (Groups 1-4). 
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their own promoters, while the second ones are encoded by 
introns of noncoding or coding transcripts and thus share 
the promoter with their host gene expression [40]. Human 
miRNA gene clusters are generally co-transcribed, but the 
individual mature miRNAs can also be regulated at post-
transcriptional levels [39]. Several known transcription 
factors, for example p53, MYC, ZEB1 and ZEB2, have 
been described as positive or negative regulators of 
miRNA expression [39]. Furthermore, miRNA regulation 
can be exerted also by epigenetic control through DNA 
methylation and histone modifications. miRNA regulation 
at post-transcriptional level is carried out through various 
mechanisms, such as RNA “tailing” through the addition 
of untemplate nucleotide at the 3’ end or adenylation, 
through RNA methylation or regulation of RNA stability 
by several specific nucleases [39]. miRNAs dysregulation 
plays a key-role in various human diseases, especially in 
cancer [34]. Of note, different tumor types have specific 
miRNA signatures compared not only to healthy tissues 
but also to other cancers. 
Calin and colleagues were the first to report in 2002 
miRNA deregulation in human cancer identifying miR-
15a/16-1 cluster deletion in chronic lymphocytic leukemia 
[41]. This deletion induces the overexpression of the anti-
apoptotic B-cell lymphoma 2 (BCL2), which is a target of 
these miRNAs [41]. Furthermore, the same investigators 
demonstrated that more than half of the known miRNA are 
located in genomic regions whose alteration is frequently 
reported in human cancers [42]. Nowadays several cancer-
associated miRNAs are known, which are described to act 
as oncosuppressor miRNAs or oncomiRs. Examples of the 
first ones are: miR-15/16, let-7, miR-200, miR-34, miR-
107 and miR-126, whereas examples of the second ones 
are: miR-221/222, miR-21 and miR-10b [37].
MICRORNA DEREGULATION IN 
MELANOMA DEVELOPMENT AND 
PROGRESSION
In the last years several studies have analyzed the 
involvement of miRNA in the progression of metastatic 
melanoma [43-53]. We will summarize here below the 
findings of a number of representative studies. 
Mueller and colleagues were the first to study 
differential miRNA expression between melanocytes and 
melanoma cell lines through a microarray-based profiling 
[43]. Using stringent criteria (up- or down-regulation more 
than 10-fold) they identified 63 miRNAs deregulated 
(49 up-regulated and 14 down-regulated) in primary 
melanomas vs normal melanocytes, which were considered 
to be associated to the early progression of melanoma. In 
a second type of analysis the same authors compared the 
miRNAome of HMB2 melanoma cells before and after 
stable transfection of an antisense melanoma inhibitory 
activity (MIA) construct. Here they observed a reverse 
trend, namely 12 up- and 34 down-regulated miRNAs 
respectively. Comparison of the first with the second 
list revealed 18 miRNAs inversely regulated, namely 
upregulated in early progression and downregulated when 
MIA was knocked down and viceversa. In a third type 
of analysis comparison of miRNA expression between 
primary melanomas and metastatic samples led to the 
identification of a smaller set of dis-regulated miRNA, 
namely 11 up-regulated and 2 down-regulated which were 
thus considered to be involved in metastatic colonization 
of melanoma cells.
A similar study was carried out by Caramuta et al 
[44], who compared miRNA expression profiles in clinical 
samples of melanoma metastasis, melanoma cell lines 
and normal melanocyte cultures. They focused on 167 
miRNAs, which were clustered in relation with clinical 
characteristics, patient survival, and mutational status for 
BRAF and NRAS [44]. These researchers, performed 
two types of analysis to identify miRNAs deregulated 
in melanomas vs melanocytes. A significant analysis of 
microarray (SAM) analysis identified 32 most important 
deregulated miRNAs, of which 13 overexpressed and 19 
down-regulated. In addition the Prediction Analysis of 
Microarrays (PAM) method revealed a minimal miRNA 
signature composed of 10 miRNAs capable to distinguish 
the two groups with a prediction accuracy of 100%. Of 
note, among these miRNAs, miR-126 had been identified 
in the previous study by Mueller et al [43]. Furthermore, 
applying the same PAM analysis Caramuta et al. identified 
six candidates miRNAs that could predict disease outcome 
[44]. Among them two were validated by RT-PCR, miR-
191 and miR-193b. High expression of miR-191 was 
confirmed to be highly correlated with better survival, 
while high expression of miR-193b was confirmed to 
correlate with poorer survival respectively [44].
Chan et al analyzed the expression of a panel of 384 
miRNAs between 42 patient derived primary melanomas 
samples with three normal melanocyte control samples 
and found eight miRNAs to be differentially expressed 
[45]. Of these eight, two, miR-183 and miR-135b are 
present in the signature identified by Muller et al [43], 
while other two, namely miR-132 and miR-211 in the 
signature by Caramuta et al [44]. The same authors 
observed that miRNA expression profiles are able to 
distinguish among melanoma subtypes such as acral 
versus non non-acral melanomas [45]. Among their most 
interesting observations was that out of 32 non-acral 
melanoma samples genotyped for a KRAS oncogene 
variant located in the 3’ untranslated region (3’UTR) 
and known to be affecting the binding site for miRNAs, 
25% were positive for the KRAS-variant, thus suggesting 
the association of this variant with the increased risk of 
developing melanomas. When they compared the KRAS-
variant group and the non-KRAS-variant one, they found 
the significant down-regulation of only one miRNA, 
miR-137 [45]. Of notice, among the genes reported to 
regulate or to be regulated by miR-137 the most relevant 
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is micropthalmia-associated transcription factor (MITF) 
[54].
In addition to large profiling data above described 
some specific miRNAs have been the object of further 
investigations during the last years. Let-7a, for example, 
which is a member of a known family of oncosuppressor 
microRNAs, has been reported to be downregulated in 
melanoma cells compared to melanocytes [55]. Moreover, 
this miRNA targets human integrin β3, which has a well-
known role in melanoma progression and invasion. 
Through experiments of transient in vitro overexpression 
and luciferase assays, was it possible to link the up-
regulation of integrin β3 occurring in melanoma cells to 
the amount of let-7a present in the cell, thus demonstrating 
that this miRNA has an oncosuppressive role in melanoma 
[55]. Moreover recent findings have attributed to this 
miRNA a key role in regulating energy metabolism in 
cancer cells by mediating mitochondrial ROS production 
with the concomitant up-regulation of oxidative stress 
responsive genes [56]. Another miRNA, which specifically 
controls melanoma cell invasion is miR-339-3p. This 
miRNA has been identified by a comprehensive functional 
screen of a human miRNA mimetic library in a cell-based 
assay for invasion [57]. This miRNA targets myeloid cell 
leukemia sequence 1 (MCL-1), a well-known oncogene 
in several human malignancies, including melanoma [58]. 
In addition miR-339-3p enforced expression is able to 
affect melanoma cell invasion not only in vitro, but also 
in a model of lung colonization in T-cells deficient mice 
[57]. Moreover our group very recently identified a novel 
oncosuppressive miRNA in metastatic melanoma, miR-
579-3p [59] whose involvement in melanoma progression 
and development of drug resistance will be described in 
detail below.
Conversely the following human poly-cistronic 
miRNA clusters have been considered to play oncogenic 
roles in melanoma. The miR-17/92 cluster, for example, 
codes for miR-17, which has been shown to increase the 
motility of melanoma cells. miR-17 targets ETV1, which 
belongs to the ETS (E-twenty six) transcription factor 
family, which has a suppressive role in melanoma [60]. 
mir-514a is a member of a cluster of miRNAs (miR-
506-514), which are involved in initiating melanocyte 
transformation and promotion of melanoma growth [61]. 
miR-146a plays a dual role in melanoma malignancy. 
Its upregulation during melanoma progression triggers 
tumor growth through inhibition of lunatic fringe (LFNG) 
and NUMB and activation of the NOTCH/PTEN/AKT 
pathway. In contrast its downregulation in Circulating 
Tumor Cells (CTC), suppresses tumor dissemination 
through modulation of the expression of ITGAV and 
ROCK1 [62, 63]. miR-638 is able to promote melanoma 
metastasis since it is overexpressed in metastatic lesions 
compared to primary melanomas [64]. This miRNA 
miRNAs, which act as facilitators of the establishment of drug resistance in human cancers, are listed in the table. Not shown 
(NS) indicates that in the corresponding studies no information about miRNAs target genes have been mentioned.
Table 3: microRNAs facilitators of drug resistance in human cancers.
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downregulates TP53INP2 oncosuppressor thus protecting 
melanoma cells from apoptosis and autophagia [64]. 
Lastly, Felicetti et al [65] showed that miR-222, a well-
known oncogenic miRNA, which is encoded together 
with miR-221 [66], drives melanoma development and 
dissemination. miR-222 is transported in exosomes to 
drive melanoma malignancy from miR-overexpressing 
cells to the recipient primary melanoma cells [65]. 
Furthermore it was possible to correlate miR-exosomal 
expression to the reduction of known miR-222 target 
genes, such as p27, and conversely to the induction of 
the PI3K/AKT pathway, thus confirming its functional 
implication in melanoma development, as like as in other 
human cancers [65].
ONCOGENIC BRAF-V600 AND MAPK 
SIGNALING ACT IN CONCERT WITH 
MIRNA DEREGULATION TO AFFECT 
MELANOMA DEVELOPMENT
The RAS-RAF-MAPK signaling pathway has a 
central role in sustaining the oncogenic and proliferative 
phenotype of melanoma cells, as well as in other human 
cancers [67]. For this reason, miRNA involvement in the 
regulation of this pathway has been the focus of intensive 
research efforts. Let-7 was the first miRNA to be described 
to directly target KRAS, one of the most important 
members of MAPK pathway, frequently mutated in human 
cancers [68]. Furthermore, polymorphisms in KRAS 
3’UTR alter let-7 binding, thus resulting in the aberrant 
activation of the MAPK pathway in non-small cell lung 
cancer [68]. On the reverse MAPK activity results in the 
aberrant expression of a subset of miRNAs in pancreatic 
cancer cells. Four miRNAs: miR-7-3, miR-34a, miR-181d, 
and miR-193b, have been preferentially associated with 
MAPK activity [69]; in particular that the promoter of host 
genes for miR-7-3 and mir-34a are both downregulated by 
the constitutive activation of MAPK [69]. Therefore there 
seems to be a reciprocal capability of selected miRNAs to 
regulated of MAPK pathway and viceversa.
The most thorough analysis of the relationship 
between the oncogenic BRAF signaling and miRNAs 
expression and function in metastatic melanoma was 
carried out by Couts at al [70]. The high relevance in 
melanoma of oncogenic BRAF-V600 mutations, which 
occur in approximately 50% of cases and their impact on 
the constitutive activation of the MAPK pathway provided 
a strong rationale for this study. First of all miRNA 
expression levels were compared between melanocytes 
and six BRAF-mutated melanoma cell lines through a 
sensitive microarray profiling platform [70]. This led 
to the identification of more than 30 miRNAs differing 
between melanocytes and melanoma cells. Most of them 
had not been previously described in melanoma, but were 
known to be oncogenic or oncosuppressive in other human 
cancers. Among them, for example, miR-17-92 was known 
to be associated to tumor progression in lung, colon cancer, 
B-cell lymphoma and glioblastoma [71]; whereas miR-
34a and let-7 family members are known oncosuppressor 
miRNAs in lung, breast, prostate, gastric cancer, 
pancreatic cancer and neuroblastoma [72, 73]. When 
miRNAs expression was analyzed in the same melanoma 
cell lines before and after treatment with MEK inhibitors 
a reciprocal miRNAs deregulation was observed in more 
than half of the cases, thus confirming the correlation 
miRNAs which act as antagonists of the establishment of drug resistance in human cancers are listed in the table.
Table 4: microRNAs antagonists of drug resistance in human cancers.
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between miRNA deregulation and activation of the MAPK 
pathway [70]. In order to provide functional insights on 
the deregulated miRNAs, the authors transfected them in 
melanoma cells and observed that 14 of them were able 
to affect cell proliferation [70]. Seven miRNAs, which 
were reduced by BRAF/MAPK signaling pathway, such 
as let-7i, miR-34a and miR-22 effectively inhibited 
melanoma cell proliferation. On the reverse, seven other 
miRNAs, including miR-17 and miR-92/95, which were 
up-regulated by BRAF/MAPK signaling pathway were 
able to increase cell proliferation. Investigators then 
proceeded to identify the molecular pathways and mRNAs 
affected by the deregulated miRNAs and were able to 
demonstrate through transient transfection and luciferase 
experiments that BRAF/MAPK regulated miRNAs 
converge on a complex combinatorial control of a specific 
set of key cancer regulatory genes involved in cell cycle/
proliferation, adhesion/invasion, signaling and survival 
[70]. It was thus possible to conclude that mutated BRAF 
exerts multiple regulatory effects on melanomagenesis 
through the induction or the repression of a complex 
network of miRNAs whose targets are responsible for the 
promotion or the suppression respectively of melanoma 
growth. However, how this network of miRNAs is 
regulated by the constitutive activation of the MAPK 
pathway still remains an open question, which will require 
further investigation. It has to be added that the association 
of BRAF mutational status with miRNA deregulation was 
also confirmed in other human cancers. For example in 
colorectal cancer (CRC) it was observed that miR-31 is 
up-regulated in V600E-BRAF mutated CRCs compared 
to wild-type CRCs and this is related to cancer-specific 
mortality [74]. As mentioned above the MAPK pathway 
can be the reciprocal target of specific microRNAs. This 
is the case of miR-340. Notably miR-340 is able to affect 
the expression of 39 out of 45 total RAS-RAF-MAPK 
components, such as BRAF, KRAS, NRAS and MYC, 
thus reducing melanoma cell growth and migration [75]. 
Furthermore Liu and colleagues, through a screening 
using a high-throughput quantitative real-time miRNA 
PCR array, identified miR-524-5p as downregulated 
in BRAF mutated melanoma cells but not in wild-type 
BRAF cells [76]. miR-524-5p targets both BRAF and 
ERK2 genes, which are the key regulators of the MAPK 
pathway. Furthermore, the same authors demonstrated that 
miR-enforced expression is able to affect melanoma cell 
migration and proliferation both in vitro and in vivo, thus 
confirming its effect on the inhibition of these two potent 
oncogenic members of the MAPK pathway [76].
In conclusion, deregulation of the MAPK pathway 
and miRNA epigenetic control strongly influence tumor 
cell fate disrupting normal homeostasis in tumors addicted 
to this pathway. We represent in the diagram in Figure 
1 the most relevant miRNAs identified by the studies 
described above, which are regulated or which regulate the 
oncogenic BRAF V600/MAPK signaling in melanoma. 
DEREGULATED MIRNAS CONVERGE 
ON A SET OF KEY INTRACELLULAR 
PATHWAYS
Both comprehensive miRNAome profiling studies 
[43-53, 70] as well as individual miRNAs analyses [55-65] 
described above have shown that deregulation of several 
miRNAs contributes to the development of melanoma. The 
emerging picture is rather complex because these studies 
identified different subsets of miRNAs, thus mirroring the 
great degree of heterogeneity of these tumors. However, 
since it is known that different miRNAs can modulate the 
activity of the same mRNAs or also of different mRNAs 
coding for members of the same signaling pathways, 
we decided to assessed whether the different miRNA 
signatures observed in different studies correspond to 
the involvement of the same key signaling pathways. To 
test our this hypothesis we decided to analyze in a greater 
detail the relationship among the miRNAs identified in the 
studies described in the previous paragraphs. 
Table 1 lists the most representative deregulated 
microRNAs in melanoma subdivided on the basis of the 
different studies analyzed: i) Group 1 - miRNA signature 
associated with early progression of melanoma by a in 
the large profiling approach described by Muller et al 
[43]; ii) Group 2 - miRNAs deregulated in melanomas 
vs melanocytes by Caramuta et al and Chan et al. [44, 
45]; iii) Group 3 -miRNAs resulted to be deregulated by 
studies involving individual miRNAs [55-65]; iv) Group 
4- miRNA signature associated specifically with BRAF 
activation and identified by Couts et al [70]. In table 1 
underlined miRNAs are those with possible prognostic 
and/or diagnostic role in melanoma as reported in some 
published studies [77, 78]. As shown in Figure 2A and 
2B, no miRNAs resulted to be in common among the four 
groups; we found only one upregulated miRNA (miR-
126) in common between groups 1 and 2, one upregulated 
miRNA in common between groups 3 and 4 (miR-222), 
four down-regulated miRNAs (miR-196a, miR-374, 
miR-454-3p and miR-324-5p) in common between the 
same groups 1 and 2 and two downregulated miRNAs in 
common between groups 2 and 4 (let-7i and miR-211). 
In order to verify if the deregulated miRNAs, 
reported in Table 1, are able to target same mRNAs and/
or signaling pathways, we predicted the putative target 
mRNAs for all these miRNAs, subdivided in the four 
groups indicated above, using three online available tools, 
a) TargetScanHuman [79], b) PITA [80], and c) Miranda 
[81]. We applied to our analysis stringent criteria, by 
only selecting mRNAs predicted in common among 
all three tools. Then, an enriched functional analysis of 
pathways was performed by the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) [82]. 
The results are shown in Supplementary Figure 1. 
Interestingly, we observed a very high overlap among the 
mRNAs targets of up- and down-regulated miRNAs [43-
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45; 55-65, 70]. Most importantly, we identified a number 
of commonly deregulated pathways where these targets 
are involved (Figure 2C and 2D). In particular, concerning 
pathways related to targets of up-regulated miRNAs we 
observed (Figure 2C) that five pathways are common 
among the four groups. Looking at pathways related to 
targets down-regulated by miRNAs (Figure 2D), we found 
that six pathways are common among all four groups. Of 
note frequently deregulated pathways are Wnt signaling 
and other cancer related pathways such as, axon guidance, 
endocytosis, melanogenesis and calcium signaling (Table 
2). The involvement of these pathways in melanoma 
development and progression has been abundantly 
reported in the literature [83-92]. Wnt signaling, for 
example, plays a key role in melanoma development 
through β-catenin physiological regulation of epidermal 
melanogenesis [84]. Melanoma cells, indeed, exhibit up-
regulated melanogenesis and defective melanosomes [85]. 
Another example of deregulated pathway is represented by 
axon guidance, a key element in the formation of neuronal 
network guided by specific receptors, called plexins [89]. 
Interestingly both plexins and their guidance molecules 
semaphorins are lost during melanoma progression [90, 
91]. Most importantly plexins are known to be down-
regulated by oncogenic BRAF V600 in metastatic 
melanoma [92], thus confirming the relevance of this 
pathway underlined by our analysis.
In summary, our analysis demonstrates that, while 
in different melanoma samples and cell lines there is 
a limited or no overlap in the number of individual 
miRNAs upregulated or downregulated, on the contrary 
the same miRNAs converge on a constant set of 
metabolic pathways, which are key to the development of 
malignancy. 
MIRNAS INVOLVEMENT IN 
RESISTANCE TO TARGETED 
THERAPIES IN BRAF-MUTATED 
MELANOMAS
Therapy of metastatic cancer is mostly based on the 
Figure 2: Comparison between the miRNAs resulted to be in common among the groups 1-4 subdivided between up-
regulated A. and down-regulated B. miRNAs, and between the related deregulated pathways C. and D. by Venn diagram (http://
bioinfogp.cnb.csic.es/tools/venny/). We show the group 1 in violet, group 2 in yellow, group 3 in green, and group 4 in pink.
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use of chemotherapy and targeted therapies [93]. However, 
durable objective and clinical responses to these therapies 
are plagued by the development of chemoresistance 
which leads to disease relapse in virtually all metastatic 
patients. Although this scenario is changing in recent 
years due to the advent of immunotherapy, it has to be 
stressed that immunotherapy is effective only in a subset 
of patients. Therefore major efforts are still directed to 
understand the molecular basis of drug resistance and to 
develop combination therapies capable to revert acquired 
resistance or, even better, to avoid the development 
of resistance. In this context it is of interest to observe 
that growing evidences point to miRNAs as key factors 
controlling the emergence of drug resistance.
Garofalo et al. for example, first showed that 
the oncogenic miR-221/222 induce TRAIL resistance 
in aggressive non-small cell lung cancer through the 
activation of the AKT pathway, by targeting PTEN and 
TIMP3 tumor suppressors [94]. Furthermore, the same 
group was able to show that the MET oncogene is involved 
in miR-221/222 activation and that miR-130a, by targeting 
MET, reduces TRAIL resistance in NSCLC cells through 
down-regulation of miR-221/222 [95]. Other investigators, 
demonstrated that miR-19 is involved in the regulation 
of multidrug resistance (MDR) through the inhibition of 
the oncosuppressor gene PTEN, thus increasing breast 
cancer cells resistance to chemotherapeutic agents [96]. 
Most important miRNAs [61, 59, 94-104, 106, 108] 
with an impact on the establishment of drug resistance 
in human cancers are reported in Table 3 and 4. Coming 
back to metastatic melanoma only few studies have 
been published about the relationship between miRNAs 
and drug resistance especially in the context of BRAFi/
MEKi based targeted therapies. miR-214, for example, 
is supposed to play a role in chemoresistance because 
it has been shown to reduce melanoma cells apoptosis 
by facilitating survival in adhesion-lacking (anoikis) 
conditions [105] and also because it is able to modulate 
drug resistance in many other human cancers, such as 
lung, ovarian, breast and cervical cancers [106]. However, 
until now, no study of miR-214 involvement in melanoma 
drug resistance has been published. In this regard it is 
important to point out that some miRNAs, such as miR-
638 and miR-579-3p, have been also described to affect 
melanoma cell apoptosis alone or in presence of BRAF 
inhibitors treatments [59, 64]. 
Some miRNAs act as “facilitators” of drug 
resistance. One such example was provided by Stark et 
al. who suggested the potential involvement of mir-514a 
in the modulation of sensitivity to BRAF inhibitors in 
melanoma cells [61]. These investigators showed that 
NF1, a known tumor suppressor [107], is a direct target 
of miR-514a [61]. Both NF1 direct silencing by specific 
silencing with siRNA, and miR-514a upregulation leading 
to decreased NF1 levels were able to strongly decrease 
drug sensitivity in short term “in vitro” cell proliferation 
assays [61]. However this study did not ask the direct 
question of whether up- or down-regulation of miR-514a 
expression is capable to affect the development of long 
term resistance and the emergence of resistant melanoma 
cell populations. Also no effort was made to determine 
changes in the expression of miR-514a between “ drug 
sensitive” vs “drug resistant” tumor samples derived from 
patients.
Very recently, it has been shown that BRAF 
inhibitors induce adaptive cell response via cytokine 
production with a strong cross-talk with miRNAs 
deregulation, which act as facilitators of drug resistance. 
Vergani and colleagues proposed that BRAFi-resistant 
melanoma cells up-regulate chemokine monocyte 
chemoattractant protein-1 (CCL2), which in turn activate 
the expression of miR-34a, miR-100 and miR-125b 
[108]. These miRNAs activation is orchestrated by HIF1 
transcription factor [109], which is also known to regulate 
CCL2 secretion [108]. In line with these findings miR-34a, 
miR-100 and miR-125b were found to be up-regulated in 
BRAFi resistant melanoma cell lines and in the biopsies 
from patients undergoing vemurafenib treatments [108]. 
Vergani and colleagues’ data are consistent with previous 
published studies, which evaluated miR-125b, miR-34a 
and miR-100 involvement in chemoresistance in other 
tumors through the targeting of proapoptotic genes [108].
An opposite mechanism of action has been 
attributed to miR-200c, member of a family of known 
oncosuppressive miRNA [110]. This miRNA has been 
proposed to counteract the establishment of drug resistance 
in melanoma by directly targeting Bmi-1, a critical factor 
involved in the maintenance of stem cells [111]. miR-
200c enforced expression reduced the expression of three 
members of the ATP-binding cassette (ABC) transporters, 
which mediate chemoresistance in melanoma, thus 
increasing both targeted therapies and chemotherapy 
mediated reduction of melanoma cell growth [111]. Also, 
the biological effects induced by miR-200c overexpression 
were phenocopied by BMI inactivation. On the reverse, 
loss of miR-200c increased Bmi-1 expression, thus 
leading to downregulation of E-cadherin, uppregulation 
of N-cadherin, and therefore mesenchymal to epithelial 
transition (MET), upregulation of ABC transporters and 
activation of the PI3K/AKT and MAPK survival pathways 
[112]. Finally miR-200c was shown to be downregulated 
in melanomas that acquire resistance to BRAF inhibitors 
compared to pretreatment tumor biopsies, in which its 
target genes are conversely up-regulated [112]. 
Finally, our group, which studies the mechanisms 
responsible for the establishment of drug resistance 
in melanoma [30, 32, 113], has identified a novel 
miRNA, miR-579-3p as a master regulator of melanoma 
progression and drug resistance [59]. This miRNA 
belongs to the miR-548 family, which is emerging as a 
new family with oncosuppressive role in several human 
tumors, including breast, ovarian, brain, lung, colon and 
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cervical cancers [114]. We identified miR-579-3p through 
the online algorithm miRò, by querying potential miRNA 
deregulated during melanoma progression in relationship 
with BRAF mutational status [115]. Of note we found that 
this miRNA has two seed regions that match the 3’-UTR 
of BRAF [79, 116]. We confirmed, through luciferase and 
transient overexpression assays its ability to target miR-
579-3p and concordantly with these data the reduction of 
melanoma cell growth and migration. In addition miR-
579-3p targets and inhibits the MDM2 oncoprotein [117]. 
Moreover, we found that low miR-579-3p expression 
correlates with worse prognosis in melanoma patients and 
that its expression is further decreased in BRAFi/MEKi 
resistant melanoma cells. In this regard we observed that 
miR-579-3p enforced expression both potentiates BRAF 
and/or MEKi anti-proliferative effects and impairs the 
establishment of resistance to BRAF inhibitors in long-
term clonogenic assay. Most importantly using matched 
tumor samples from melanoma patients before and after 
development of resistance, we observed that miR-579-3p 
is strongly downregulated in tumor biopsies from the same 
patient after the development of resistance and that this 
coincides with a reciprocal regulation of the expression 
of its target oncogenes BRAF and MDM-2 [59]. We are 
currently investigating the role of a large network of 
deregulated miRNAs as major players in the establishment 
of drug resistance in melanoma through the analysis of 
the whole miRNome profile during the development of 
resistance. Our unpublished results highlight a gradual 
deregulation of a growing number of miRNAs, which 
rewire a complex network of intracellular pathways.  
All together these studies point to the involvement of 
a number of miRNAs either as promoters or as antagonists 
of resistance (see Table 3 and 4) and show a complex 
mechanism of regulation by which during the progression 
of resistance the first groups undergoes upregulation 
whereas the second undergoes downregulation. How 
is this process coordinated and which are the main 
mechanisms controlling the expression of this network of 
miRNAs will require further studies.
CONCLUSIONS
The Cancer Genome Atlas (TCGA) allowed the 
identification of four genetic subtypes of cutaneous 
melanoma, BRAF mutant (the most common condition 
responsible for more than 50% of cases), RAS mutant, 
NF1 mutant, and Triple Wild-Type [118]. Mutations in 
each of the major driver genes, BRAF, RAS, and NF1, 
all contribute to deregulation of the MAPK/ERK pathway, 
leading to uncontrolled cell growth. As recapitulated in 
this review genetic changes trigger a complex rewiring 
of intracellular pathways, which involve as major players 
several microRNAs. How this is accomplished, i.e. 
how MAPK/ERK deregulation influences the pattern of 
microRNA expression remains still largely unexplored. 
Importantly, when normal expression of specific miRNAs 
is restored in melanomas, reversion of the malignant 
phenotype is observed both in in vitro and in in vivo 
assays, which demonstrates the central role of miRNA in 
disease pathogenesis. 
miRNA deregulation, albeit heterogeneous in 
different patients and tumor samples (see Figure 1 and 2), 
constantly converges in a defined subset of intracellular 
pathways. Indeed our bioinformatic analysis of profiling 
data from different studies postulates the involvement 
of specific pathways such as in particular Wnt, axon 
guidance and exocytosis. Although this intriguing finding 
will require further validations in the lab, we believe that 
identification of pathways commonly deregulated by 
miRNAs in melanoma may lead to a better understanding 
of disease evolution and to the discovery of additional 
targets for therapeutic intervention. 
Most important for its therapeutic and diagnostic 
implications is the increasing evidence that miRNA 
deregulation is heavily responsible for the development 
of resistance to target therapies. During the development 
of resistance melanoma select cells with low expression 
of selected miRNAs, such as miR-200c and miR-579-3p, 
two potent oncosuppressors acting apparently on different 
and complementary pathways [59, 111, 112]. Restoration 
of their expression potentiates the effect of MAPK 
pathway inhibitory drugs and impairs the establishment 
of resistance. While it will be important in the future 
to dissect the molecular mechanism leading to their 
downregulation, from a therapeutic perspective our strong 
hope is on the improvement of robust in vivo delivery 
technologies for miRNA mimics capable to restore their 
normal expression profile in the tumor [119]. Finally, 
since miRNAs are very stable in human fluids compared 
to mRNAs because they could be packaged in exosomes 
or associated with RNA-binding proteins or lipoprotein 
complexes, which protect them from degradation [120, 
121], deregulated miRNA could be used as successful 
biomarkers in patient plasma and serum, able to early 
predict resistance to therapies [122-125].
ACKNOWLEDGMENTS
This study was supported in part by AIRC grants 
IG15216 to G. Ciliberto and IG17009 to R. Mancini. L. 
Fattore is the recipient of a FIRC Fellowship. We are 
grateful to Alessandra Trocino for editorial assistance.
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
REFERENCES
1. Tsao H, Chin L, Garraway LA, Fisher ED. Melanoma: from 
mutations to medicine. Genes Dev. 2012; 26:1131-55. doi: 
Oncotarget22273www.impactjournals.com/oncotarget
10.1101/gad.191999.112.
2. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, 
Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer 
EA, Parulekar W, Markovic SN, Saxman S et al. Meta-
analysis of phase II cooperative group trials in metastatic 
stage IV melanoma to determine progression-free and 
overall survival benchmarks for future phase II trials. J Clin 
Oncol. 2008; 26:527-34. doi: 10.1200/JCO.2007.12.7837.
3. Ascierto PA, Marincola FM. 2015: The Year of Anti-PD-1/
PD-L1s Against Melanoma and Beyond. EBioMedicine. 
2015; 2:92-3. doi: 10.1016/j.ebiom.2015.01.011. 
4. Menzies AM, Long GV. Systemic treatment for BRAF 
mutant melanoma: where do we go next? Lancet Oncol. 
2014; 15:e371-81. doi: 10.1016/S1470-2045(14)70072-5.
5. Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, 
Grimaldi AM, Maio M, Palmieri G, Testori A, Marincola 
FM, Mozzillo N. The role of BRAF V600 mutation in 
melanoma. J Transl Med. 2012; 10:85. doi: 10.1186/1479-
5876-10-85.
6. Inamdar GS1, Madhunapantula SV, Robertson GP. 
Targeting the MAPK pathway in melanoma: why some 
approaches succeed and other fail. Biochem Pharmacol. 
2010; 80:624-37. doi: 10.1016/j.bcp.2010.04.029. 
7. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, 
Sosman JA, O’Dwyer PJ, Lee RJ, Grippo JF, Nolop K, 
Chapman PB. Inhibition of mutated, activated BRAF in 
metastatic melanoma. N Engl J Med. 2010; 363:809-19. 
doi: 10.1056/NEJMoa1002011. 
8. Zhang C, Spevak W, Zhang Y, Burton EA, Ma Y, Habets G, 
Zhang J, Lin J, Ewing T, Matusow B, Tsang G, Marimuthu 
A, Cho H et al. RAF inhibitors that evade paradoxical 
MAPK pathway activation. Nature. 2015; 526:583-6. doi: 
10.1038/nature14982. 
9. Poulikakos PI, Zhang C, Bollag G Shokat KM, Rosen 
N. RAF inhibitors transactivate RAF dimers and ERK 
signaling in cells with wild-type BRAF. Nature. 2010; 
464:427-30. doi: 10.1038/nature08902.
10. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto 
P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, 
Hogg D, Lorigan P, Lebbe C, et al. Improved survival 
with vemurafenib in melanoma with BRAF V600E 
mutation. N Engl J Med. 2011; 364:2507-16. doi: 10.1056/
NEJMoa1103782. 
11. Lo RS. Combinatorial therapies to overcome B-RAF 
inhibitor resistance in melanomas. Pharmacogenomics. 
2012; 13:125-8. doi: 10.2217/pgs.11.166.
12. Corcoran RB, Settleman J, Engelman JA. Potential 
Therapeutic Strategies to Overcome Acquired Resistance 
to BRAF or MEK Inhibitors in BRAF Mutant Cancers. 
Oncotarget. 2011; 4:336-46. doi: 10.18632/oncotarget.262.
13. Little AS1, Smith PD, Cook SJ. Mechanisms of acquired 
resistance to ERK1/2 pathway inhibitors. Oncogene. 2013; 
32:1207-15. doi: 10.1038/onc.2012.160. 
14. Spagnolo F, Ghiorzo P, Queirolo P. Overcoming resistance 
to BRAF inhibition in BRAF-mutated metastatic 
melanoma. Oncotarget. 2014; 5:10206-21. doi: 10.18632/
oncotarget.2602
15. Gibney GT1, Messina JL, Fedorenko IV, Sondak VK, 
Smalley KS. Paradoxical oncogenesis--the long-term effects 
of BRAF inhibition in melanoma. Nat Rev Clin Oncol. 
2013; 10:390-9. doi: 10.1038/nrclinonc.2013.83. 
16. Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay 
G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, 
Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C 
et al. Combined vemurafenib and cobimetinib in BRAF-
mutated melanoma. N Engl J Med. 2014; 371:1867-76. doi: 
10.1056/NEJMoa1408868.
17. Robert C, Karaszewska B, Schachter J, Rutkowski P, 
Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer 
R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, 
Krajsova I et al. Improved overall survival in melanoma 
with combined dabrafenib and trametinib. N Engl J Med. 
2015; 372:30-9. doi: 10.1056/NEJMoa1412690. 
18. Grob JJ, Amonkar MM, Karaszewska B, Schachter J, 
Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, 
Grange F, Chiarion-Sileni V, Rutkowski P, Lichinitser M, 
Levchenko E et al. Comparison of dabrafenib and trametinib 
combination therapy with vemurafenib monotherapy on 
health-related quality of life in patients with unresectable 
or metastatic cutaneous BRAF Val600-mutation-positive 
melanoma (COMBI-v): results of a phase 3, open-label, 
randomised trial. Lancet Oncol. 2015; 16:1389-98. doi: 
10.1016/S1470-2045(15)00087-X.
19. Krepler C, Xiao M, Sproesser K, Brafford PA, Shannan B, 
Beqiri M, Liu Q, Xu W, Garman B, Nathanson KL, Xu 
X, Karakousis GC, Mills GB et al. Personalized Preclinical 
Trials in BRAF Inhibitor-Resistant Patient-Derived 
Xenograft Models Identify Second-Line Combination 
Therapies. Clin Cancer Res. 2016; 22:1592-602. doi: 
10.1158/1078-0432.CCR-15-1762. 
20. Ascierto PA, Marincola FM, Atkins MB. What’s new in 
melanoma? Combination! J Transl Med. 2015; 13:213. doi: 
10.1186/s12967-015-0582-1. 
21. Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, 
Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman 
JA, Kefford RF, Long GV et al. Melanoma whole-exome 
sequencing identifies (V600E) B-RAF amplification-
mediated acquired B-RAF inhibitor resistance. Nat 
Commun. 2012; 3:724. doi: 10.1038/ncomms1727.
22. Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, 
Koya RC, Samatar AA, Khanlou N, Braun J, Ruchalski K, 
Seifert H, Larkin J et al. Tunable-combinatorial mechanisms 
of acquired resistance limit the efficacy of BRAF/MEK 
cotargeting but result in melanoma drug addiction. Cancer 
Cell. 2015; 27:240-56. doi: 10.1016/j.ccell.2014.11.018. 
23. Nazarian R, Shi H, Wang Q, Kong X, Koya R.C, Lee H, 
Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson 
SF, McArthur G et al. Melanomas acquire resistance to 
B-RAF(V600E) inhibition by RTK or N-RAS upregulation. 
Oncotarget22274www.impactjournals.com/oncotarget
Nature. 2010; 468:973-7. doi: 10.1038/nature09626. 
24. Poulikakos, PI, Persaud Y, Janakiraman M, Kong X, 
Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT 
Salton M, Dahlman KB, Tadi M et al. RAF inhibitor 
resistance is mediated by dimerization of aberrantly spliced 
BRAF(V600E). Nature. 2011; 480:387-90. doi: 10.1038/
nature10662.
25. Shi H, Moriceau G, Kong X, Koya RC, Nazarian R, Pupo 
GM, Bacchiocchi A, Dahlman KB, Chmielowski B, Sosman 
JA Halaban R, Kefford RF, Long GV et al. Preexisting 
MEK1 exon 3 mutations in V600E/KBRAF melanomas do 
not confer resistance to BRAF inhibitors. Cancer Discov. 
2012; 2:414-24. doi: 10.1158/2159-8290.CD-12-0022. 
26. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau 
G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley 
MC, Kefford RF, Chmielowski B et al. Acquired resistance 
and clonal evolution in melanoma during BRAF inhibitor 
therapy. Cancer Discov. 2014; 4:80-93. doi: 10.1158/2159-
8290.CD-13-0642. 
27. Wellbrock C, Arozarena I. The Complexity of the ERK/
MAP-Kinase Pathway and the Treatment of Melanoma 
Skin Cancer. Front Cell Dev Biol. 2016; 4:33. doi: 10.3389/
fcell.2016.00033. 
28. Kugel CH 3rd, Aplin AE. Adaptive resistance to RAF 
inhibitors in melanoma. Pigment Cell Melanoma Res. 2014; 
27(6):1032-8. doi: 10.1111/pcmr.12264. 
29. Smith MP, Brunton H, Rowling EJ, Ferguson J, Arozarena 
I, Miskolczi Z, Lee JL, Girotti MR, Marais R, Levesque 
MP, Dummer R, Frederick DT, Flaherty KT et al. Inhibiting 
Drivers of Non-mutational Drug Tolerance Is a Salvage 
Strategy for Targeted Melanoma Therapy. Cancer Cell. 
2016; 29:270-84. doi: 10.1016/j.ccell.2016.02.003.
30. Fattore L, Marra E, Pisanu ME, Noto A, de Vitis C, 
Belleudi F, Aurisicchio L, Mancini R, Torrisi MR, Ascierto 
PA, Ciliberto G. Activation of an early feedback survival 
loop involving phospho-ErbB3 is a general response of 
melanoma cells to RAF/MEK inhibition and is abrogated 
by anti-ErbB3 antibodies. J Transl Med. 2013; 11:180. doi: 
10.1186/1479-5876-11-180.
31. Abel EV, Basile KJ, Kugel CH 3rd, Witkiewicz AK, 
Le K, Amaravadi RK, Karakousis GC, Xu X, Xu W, 
Schuchter LM, Lee JB, Ertel A, Fortina P et al. Melanoma 
adapts to RAF/MEK inhibitors through FOXD3-mediated 
upregulation of ERBB3. J Clin Invest. 2013; 123:2155-68. 
doi: 10.1172/JCI65780. 
32. Fattore L, Malpicci D, Marra E, Belleudi F, Noto A, De 
Vitis C, Pisanu ME2, Coluccia P, Camerlingo R, Roscilli 
G, Ribas A, Di Napoli A, Torrisi MR et al. Combination of 
antibodies directed against different ErbB3 surface epitopes 
prevents the establishment of resistance to BRAF/MEK 
inhibitors in melanoma. Oncotarget. 2015; 6:24823-41. doi: 
10.18632/oncotarget.4485.
33. Calin GA, Croce CM. MicroRNA signatures in human 
cancers. Nat Rev Cancer. 2006; 6:857-66. 10.1038/nrc1997
34. Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol. 
2012; 6:590-610. doi: 10.1016/j.molonc.2012.09.006. 
35. Lai EC. Two decades of miRNA biology: lessons 
and challenges. RNA. 2015; 21:675-7. doi: 10.1261/
rna.051193.115.
36. Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: 
biomarkers, functions and therapy. Trends Mol Med. 2014; 
20:460-9. doi: 10.1016/j.molmed.2014.06.005. 
37. Acunzo M, Romano G, Wernicke D, Croce CM. MicroRNA 
and cancer--a brief overview. Adv Biol Regul. 2015; 57:1-
9. doi: 10.1016/j.jbior.2014.09.013. 
38. Wilczynska A, Bushell M. The complexity of miRNA-
mediated repression. Cell Death Differ. 2015; 22:22-33. doi: 
10.1038/cdd.2014.112. 
39. Ha M, Kim VN. Regulation of microRNA biogenesis. 
Nat Rev Mol Cell Biol. 2014; 15:509-24. doi: 10.1038/
nrm3838. 
40. Ramalingam P, Palanichamy JK, Singh A, Das P, Bhagat 
M, Kassab MA, Sinha S, Chattopadhyay P. Biogenesis 
of intronic miRNAs located in clusters by independent 
transcription and alternative splicing. RNA. 2014; 20:76-
87. doi: 10.1261/rna.041814.113. 
41. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch 
E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps 
T, Negrini M et al. Frequent deletions and down-regulation 
of micro- RNA genes miR15 and miR16 at 13q14 in 
chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 
2002; 99:15524-9. doi: 10.1073/pnas.242606799
42. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, 
Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, 
Croce CM. Human microRNA genes are frequently located 
at fragile sites and genomic regions involved in cancers. 
Proc Natl Acad Sci U S A. 2004; 101:2999-3004. doi: 
10.1073/pnas.0307323101.
43. Mueller DW, Rehli M, Bosserhoff AK. miRNA expression 
profiling in melanocytes and melanoma cell lines reveals 
miRNAs associated with formation and progression of 
malignant melanoma. J Invest Dermatol. 2009; 129:1740-
51. doi: 10.1038/jid.2008.452. 
44. Caramuta S, Egyházi S, Rodolfo M, Witten D, Hansson 
J, Larsson C, Lui WO. MicroRNA expression profiles 
associated with mutational status and survival in malignant 
melanoma. J Invest Dermatol. 2010; 130:2062-70. doi: 
10.1038/jid.2010.63. 
45. Chan E, Patel R, Nallur S, Ratner E, Bacchiocchi A, Hoyt 
K, Szpakowski S, Godshalk S, Ariyan S, Sznol M, Halaban 
R, Krauthammer M, Tuck D et al. MicroRNA signatures 
differentiate melanoma subtypes. Cell Cycle. 2011; 
10:1845-52. doi: 10.4161/cc.10.11.15777.
46. Poliseno L, Haimovic A, Segura MF, Hanniford D, Christos 
PJ, Darvishian F, Wang J, Shapiro RL, Pavlick AC, Berman 
RS, Hernando E, Zavadil J, Osman I. Histology-specific 
microRNA alterations in melanoma. J Invest Dermatol. 
2012; 132:1860-8. doi: 10.1038/jid.2011.451. 
Oncotarget22275www.impactjournals.com/oncotarget
47. Li Z, Yu X, Shen J, Jiang Y. MicroRNA dysregulation in 
uveal melanoma: a new player enters the game. Oncotarget. 
2015; 6:4562-8. doi: 10.18632/oncotarget.2923.
48. Kozubek J, Ma Z, Fleming E, Duggan T, Wu R, Shin 
DG, Dadras SS. In-depth characterization of microRNA 
transcriptome in melanoma. PLoS One. 2013; 8:e72699. 
doi: 10.1371/journal.pone.0072699. 
49. Hanniford D, Segura MF, Zhong J, Philips E, Jirau-
Serrano X, Darvishian F, Berman RS, Shapiro RL, Pavlick 
AC, Brown B, Osman I, Hernando E. Identification of 
metastasis-suppressive microRNAs in primary melanoma. 
J Natl Cancer Inst. 2015; 107. pii: dju494. doi: 10.1093/jnci/
dju494. 
50. Xu Y, Brenn T, Brown ER, Doherty V, Melton DW. 
Differential expression of microRNAs during melanoma 
progression: miR-200c, miR-205 and miR-211 are 
downregulated in melanoma and act as tumour suppressors. 
Br J Cancer. 2012; 106:553-61. doi: 10.1038/bjc.2011.568. 
51. Sand M, Skrygan M, Sand D, Georgas D, Gambichler 
T, Hahn SA, Altmeyer P, Bechara FG. Comparative 
microarray analysis of microRNA expression profiles 
in primary cutaneous malignant melanoma, cutaneous 
malignant melanoma metastases, and benign melanocytic 
nevi. Cell Tissue Res. 2013; 351:85-98. doi: 10.1007/
s00441-012-1514-5. 
52. Philippidou D, Schmitt M, Moser D, Margue C, Nazarov 
PV, Muller A, Vallar L, Nashan D, Behrmann I, Kreis S. 
Signatures of microRNAs and selected microRNA target 
genes in human melanoma. Cancer Res. 2010; 70:4163-73. 
doi: 10.1158/0008-5472.CAN-09-4512. 
53. Stark MS, Tyagi S, Nancarrow DJ, Boyle GM, Cook 
AL, Whiteman DC, Parsons PG, Schmidt C, Sturm 
RA, Hayward NK. Characterization of the Melanoma 
miRNAome by Deep Sequencing. PLoS One. 2010; 
5:e9685. doi: 10.1371/journal.pone.0009685. 
54. Bemis LT, Chen R, Amato CM, Classen EH, Robinson 
SE, Coffey DG, Erickson PF, Shellman YG, Robinson 
WA. MicroRNA-137 targets microphthalmia-associated 
transcription factor in melanoma cell lines. Cancer Res. 
2008; 68:1362-8. doi: 10.1158/0008-5472.CAN-07-2912.
55. Müller DW, Bosserhoff AK. Integrin beta 3 expression 
is regulated by let-7a miRNA in malignant melanoma. 
Oncogene. 2008; 27:6698-706. doi: 10.1038/onc.2008.282. 
56. Serguienko A, Grad I, Wennerstrøm AB, Meza-Zepeda 
LA, Thiede B, Stratford EW, Myklebost O, Munthe E. 
Metabolic reprogramming of metastatic breast cancer and 
melanoma by let-7a microRNA. Oncotarget. 2015; 6:2451-
65. doi: 10.18632/oncotarget.3235.
57. Weber CE, Luo C, Hotz-Wagenblatt A, Gardyan A, Kordaß 
T, Holland-Letz T, Osen W, Eichmuller SB. miR-339-3p 
is a tumor suppressor in melanoma. Cancer Res. 2016; 
76:3562-71. doi: 10.1158/0008-5472.CAN-15-2932. 
58. McKee CS, Hill DS, Redfern CP, Armstrong JL, Lovat PE. 
Oncogenic BRAF signalling increases Mcl-1 expression 
in cutaneous metastatic melanoma. Exp Dermatol. 2013; 
22:767-9. doi: 10.1111/exd.12254.
59. Fattore L, Mancini R, Acunzo M, Romano G, Laganà A, 
Pisanu ME, Malpicci D, Madonna G, Mallardo D, Capone 
M, Fulciniti F, Mazzucchelli L, Botti G et al. miR-579-3p 
controls melanoma progression and resistance to target 
therapy. Proc Natl Acad Sci U S A. 2016; 113:E5005-13. 
doi: 10.1073/pnas.1607753113. 
60. Cohen R, Greenberg E, Nemlich Y, Schachter J, Markel 
G. miR-17 regulates melanoma cell motility by inhibiting 
the translation of ETV1. Oncotarget. 2015; 6:19006-16. doi: 
10.18632/oncotarget.4147.
61. Stark MS, Bonazzi VF, Boyle GM, Palmer JM, Symmons 
J, Lanagan CM, Schmidt CW, Herington AC, Ballotti R, 
Pollock PM, Hayward NK. miR-514a regulates the tumour 
suppressor NF1 and modulates BRAFi sensitivity in 
melanoma. Oncotarget. 2015; 6:17753-63. doi: 10.18632/
oncotarget.3924.
62. Raimo M, Orso F, Grassi E, Cimino D, Penna E, De Pitta 
C, Stadler MB, Primo L, Calautti E, Quaglino P. Provero 
P, Taverna D. miR-146a Exerts Differential Effects on 
Melanoma Growth and Metastatization. Mol Cancer Res. 
2016; 14:548-62. doi: 10.1158/1541-7786.MCR-15-0425-T. 
63. Forloni M, Dogra SK, Dong Y, Conte D Jr, Ou J, Zhu LJ, 
Deng A, Mahalingam M, Green MR, Wajapeyee N. miR-
146a promotes the initiation and progression of melanoma 
by activating Notch signaling. Elife. 2014; 3:e01460. doi: 
10.7554/eLife.01460.
64. Bhattacharya A, Schmitz U, Raatz Y, Schönherr M, 
Kottek T, Schauer M, Franz S, Saalbach A, Anderegg U, 
Wolkenhauer O, Schadendorf D, Simon JC, Magin T et 
al. miR-638 promotes melanoma metastasis and protects 
melanoma cells from apoptosis and autophagy. Oncotarget. 
2015; 6:2966-80. doi: 10.18632/oncotarget.3070.
65. Felicetti F, De Feo A, Coscia, Puglisi R4, Pedini F, Pasquini 
L, Bellenghi M, Errico MC, Pagani E, Carè A. Exosome-
mediated transfer of miR-222 is sufficient to increase tumor 
malignancy in melanoma. J Transl Med. 2016; 14:56. doi: 
10.1186/s12967-016-0811-2. 
66. Garofalo M, Quintavalle C, Romano G, Croce CM, 
Condorelli G. miR221/222 in cancer: their role in tumor 
progression and response to therapy. Curr Mol Med. 2012; 
12:27-33.
67. Santarpia L, Lippman SM, El-Naggar AK. Targeting 
the MAPK-RAS-RAF signaling pathway in cancer 
therapy. Expert Opin Ther Targets. 2012; 16:103-19. doi: 
10.1517/14728222.2011.645805. 
68. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis 
R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ. 
RAS is regulated by the let-7 microRNA family. Cell. 2005; 
120:635-47. doi: 10.1016/j.cell.2005.01.014.
69. Ikeda Y, Tanji E, Makino N, Kawata S, Furukawa T. 
MicroRNAs associated with mitogen-activated protein 
kinase in human pancreatic cancer. Mol Cancer Res. 2012; 
Oncotarget22276www.impactjournals.com/oncotarget
10:259-69. doi: 10.1158/1541-7786.MCR-11-0035. 
70. Couts KL, Anderson EM, Gross MM, Sullivan K, Ahn NG. 
Oncogenic B-Raf signaling in melanoma cells controls a 
network of microRNAs with combinatorial functions. 
Oncogene. 2013; 32:1959-70. doi: 10.1038/onc.2012.209. 
71. Mendell JT. miRiad roles for the miR-17-92 cluster in 
development and disease. Cell. 2008; 133:217-22. doi: 
10.1016/j.cell.2008.04.001. 
72. Roush S, Slack FJ. The let-7 family of microRNAs. Trends 
Cell Biol. 2008; 18:505-16. doi: 10.1016/j.tcb.2008.07.007. 
73. Hermeking H. The miR-34 family in cancer and apoptosis. 
Cell Death Differ. 2010; 17:193-9. doi: 10.1038/
cdd.2009.56. 
74. Nosho K, Igarashi H, Nojima M, Ito M, Maruyama R, 
Yoshii S, Naito T, Sukawa Y, Mikami M, Sumioka W, 
Yamamoto E, Kurokawa S, Adachi Y et al. Association 
of microRNA-31 with BRAF mutation, colorectal cancer 
survival and serrated pathway. Carcinogenesis. 2014; 
35:776-83. doi: 10.1093/carcin/bgt374. 
75. Strong AM, Setaluri V, Spiegelman VS. MicroRNA-340 as 
a modulator of RAS-RAF-MAPK signaling in melanoma. 
Arch Biochem Biophys. 2014; 563:118-24. doi: 10.1016/j.
abb.2014.07.012. 
76. Liu SM, Lu J, Lee HC, Chung FH, Ma N. miR-524-5p 
suppresses the growth of oncogenic BRAF melanoma by 
targeting BRAF and ERK2. Oncotarget. 2014; 5:9444-59. 
doi: 10.18632/oncotarget.2452.
77. Stark MS, Klein K, Weide B, Haydu LE, Pflugfelder A, 
Tang YH, Palmer JM, Whiteman DC, Scolyer RA, Mann 
GJ, Thompson JF, Long GV, Barbour AP et al. The 
Prognostic and Predictive Value of Melanoma-related 
MicroRNAs Using Tissue and Serum: A MicroRNA 
Expression Analysis. EBioMedicine. 2015; 2:671-80. doi: 
10.1016/j.ebiom.2015.05.011. 
78. Mirzaei H, Gholamin S, Shahidsales S, Sahebkar A, Jaafari 
MR, Mirzaei HR, Hassanian SM, Avan A. MicroRNAs 
as potential diagnostic and prognostic biomarkers in 
melanoma. Eur J Cancer. 2016; 53:25-32. doi: 10.1016/j.
ejca.2015.10.009. 
79. Lewis, BP, Burge, CB, Bartel DP. Conserved seed pairing, 
often flanked by adenosines, indicates that thousands of 
human genes are microRNA targets. Cell. 2005; 120:15-
20. doi: 10.1016/j.cell.2004.12.035
80. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. The 
role of site accessibility in microRNA target recognition. 
Nat Genet. 2007; 39:1278-84. doi: 10.1038/ng2135.
81. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks 
DS. miRanda application: Human MicroRNA targets. PLoS 
Biol. 2004; 2:e363. doi: 10.1371/journal.pbio.0020363.
82. Huang DW, Sherman BT, Lempicki RA. Bioinformatics 
enrichment tools: paths toward the comprehensive 
functional analysis of large gene lists. Nucleic Acids Res. 
2009; 37:1-13. doi: 10.1093/nar/gkn923. 
83. Chien AJ, Moore EC, Lonsdorf AS, Kulikauskas RM, 
Rothberg BG, Berger AJ, Major MB, Hwang ST, Rimm 
DL, Moon RT. Activated Wnt/beta-catenin signaling 
in melanoma is associated with decreased proliferation 
in patient tumors and a murine melanoma model. Proc 
Natl Acad Sci U S A. 2009; 106:1193-8. doi: 10.1073/
pnas.0811902106. 
84. Bellei B, Pitisci A, Catricalà C, Larue L, Picardo M. Wnt/β-
catenin signaling is stimulated by α-melanocyte-stimulating 
hormone in melanoma and melanocyte cells: implication 
in cell differentiation. Pigment Cell Melanoma Res. 2011; 
24:309-25. doi: 10.1111/j.1755-148X.2010.00800.x. 
85. Riley PA. Melanogenesis and melanoma. Pigment Cell Res. 
2003 Oct;16:548-52. PMID: 12950735
86. Santoni G, Farfariello V. TRP channels and cancer: new 
targets for diagnosis and chemotherapy. Endocr Metab 
Immune Disord Drug Targets. 2011; 11:54-67.
87. Guo H, Carlson JA, Slominski A. Role of TRPM in 
melanocytes and melanoma. Exp Dermatol. 2012; 21:650-
4. doi: 10.1111/j.1600-0625.2012.01565.x. 
88. Mosesson Y, Mills GB, Yarden Y. Derailed endocytosis: an 
emerging feature of cancer. Nat Rev Cancer. 2008; 8:835-
50. doi: 10.1038/nrc2521. 
89. Negishi M, Oinuma I, Katoh H. Plexins: axon guidance and 
signal transduction. Cell Mol Life Sci. 2005; 62:1363-71. 
doi: 10.1007/s00018-005-5018-2
90. Lazova R, Gould Rothberg BE, Rimm D, Scott G. The 
semaphorin 7A receptor Plexin C1 is lost during melanoma 
metastasis. Am J Dermatopathol. 2009; 31:177-81. doi: 
10.1097/DAD.0b013e318196672d.
91. Chen Y, Soong J, Mohanty S, Xu L, Scott G. The neural 
guidance receptor Plexin C1 delays melanoma progression. 
Oncogene. 2013; 32:4941-9. doi: 10.1038/onc.2012.511. 
92. Argast GM, Croy CH, Couts KL, Zhang Z, Litman E, Chan 
DC, Ahn NG. Plexin B1 is repressed by oncogenic B-Raf 
signaling and functions as a tumor suppressor in melanoma 
cells. Oncogene. 2009; 28:2697-709. doi: 10.1038/
onc.2009.133. 
93. Sawyers C. Targeted cancer therapy. Nature. 2004; 
432:294-7. doi: 10.1038/nature03095.
94. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, 
Ngankeu A, Taccioli C, Pichiorri F, Alder H, Secchiero P, 
Gasparini P, Gonelli A, Costinean S et al. miR-221&222 
regulate TRAIL resistance and enhance tumorigenicity 
through PTEN and TIMP3 downregulation. Cancer Cell. 
2009; 16:498-509. doi: 10.1016/j.ccr.2009.10.014.
95. Acunzo M, Visone R, Romano G, Veronese A, Lovat F, 
Palmieri D, Bottoni A, Garofalo M, Gasparini P, Condorelli 
G, Chiariello M, Croce CM. miR-130a targets MET and 
induces TRAIL-sensitivity in NSCLC by downregulating 
miR-221 and 222. Oncogene. 2012; 31:634-42. doi: 
10.1038/onc.2011.260. 
96. Liang Z, Li Y, Huang K, Wagar N, Shim H. Regulation of 
miR-19 to breast cancer chemoresistance through targeting 
PTEN. Pharm Res. 2011; 28:3091-100. doi: 10.1007/
Oncotarget22277www.impactjournals.com/oncotarget
s11095-011-0570-y. 
97. Li H, Yang BB. Stress response of glioblastoma cells 
mediated by miR-17-5p targeting PTEN and the passenger 
strand miR-17-3p targeting MDM2. Oncotarget. 2012; 
3:1653-68. doi: 10.18632/oncotarget.810.
98. Li Z, Hu S, Wang J, Cai J, Xiao L, Yu L, Wang Z. MiR-27a 
modulates MDR1/P-glycoprotein expression by targeting 
HIPK2 in human ovarian cancer cells. Gynecol Oncol. 
2010; 119:125-30. doi: 10.1016/j.ygyno.2010.06.004. 
99. Li J1, Wang Y, Song Y, Fu Z, Yu W. miR-27a regulates 
cisplatin resistance and metastasis by targeting RKIP in 
human lung adenocarcinoma cells. Mol Cancer. 2014; 
13:193. doi: 10.1186/1476-4598-13-193.
100. Wei X, Wang W, Wang L, Zhang Y, Zhang X, Chen 
M, Wang F, Yu J, Ma Y, Sun G. MicroRNA-21 induces 
5-fluorouracil resistance in human pancreatic cancer cells 
by regulating PTEN and PDCD4. Cancer Med. 2016; 
5:693-702. doi: 10.1002/cam4.626. 
101. Zhu X, Li H, Long L, Hui L, Chen H, Wang X, Shen H, 
Xu W. miR-126 enhances the sensitivity of non-small cell 
lung cancer cells to anticancer agents by targeting vascular 
endothelial growth factor Acta Biochim Biophys Sin 
(Shanghai). 2012; 44:519-26. doi: 10.1093/abbs/gms026. 
102. Zhao X, Yang L, Hu J. Down-regulation of miR-27a 
might inhibit proliferation and drug resistance of gastric 
cancer cells. J Exp Clin Cancer Res. 2011; 30:55. doi: 
10.1186/1756-9966-30-55.
103. Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, 
Nozawa Y, Deguchi T, Ito M. Effects of miR-34a on cell 
growth and chemoresistance in prostate cancer PC3 cells. 
Biochem Biophys Res Commun. 2008; 377:114-9. doi: 
10.1016/j.bbrc.2008.09.086. 
104. Ji Q, Hao X, Meng Y, Zhang M, Desano J, Fan D, Xu L. 
Restoration of tumor suppressor miR-34 inhibits human 
p53-mutant gastric cancer tumorspheres. BMC Cancer. 
2008; 8:266. doi: 10.1186/1471-2407-8-266. 
105. Penna E, Orso F, Cimino D, Tenaglia E, Lembo A, Quaglino 
E, Poliseno L, Haimovic A, Osella-Abate S, De Pittà C, 
Pinatel E, Stadler MB, Provero P et al. microRNA-214 
contributes to melanoma tumour progression through 
suppression of TFAP2C. EMBO J. 2011; 30:1990-2007. 
doi: 10.1038/emboj.2011.102. 
106. Penna E, Orso F, Taverna D. miR-214 as a key hub that 
controls cancer networks: small player, multiple functions. 
J Invest Dermatol. 2015; 135:960-9. doi: 10.1038/
jid.2014.479. 
107. Nissan MH, Pratilas CA, Jones AM, Ramirez R, Won 
H, Liu C, Tiwari S, Kong L, Hanrahan AJ, Yao Z, 
Merghoub T, Ribas A, Chapman PB et al. Loss of NF1 
in cutaneous melanoma is associated with RAS activation 
and MEK dependence. Cancer Res. 2014; 74:2340-50. doi: 
10.1158/0008-5472.CAN-13-2625. 
108. Vergani E, Di Guardo L, Dugo M, Rigoletto S, Tragni G, 
Ruggeri R, Perrone F, Tamborini E, Gloghini A, Arienti 
F, Vergani B, Deho P, De Cecco L et al. Overcoming 
melanoma resistance to vemurafenib by targeting CCL2-
induced miR-34a, miR-100 and miR-125b. Oncotarget. 
2016; 7:4428-41. doi: 10.18632/oncotarget.6599.
109. Mojsilovic-Petrovic J, Callaghan D, Cui H, Dean C, 
Stanimirovic DB, Zhang W. Hypoxia-inducible factor-1 
(HIF-1) is involved in the regulation of hypoxia-stimulated 
expression of monocyte chemoattractant protein-1 
(MCP-1/CCL2) and MCP-5 (Ccl12) in astrocytes. J 
Neuroinflammation. 2007; 4:12. doi: 10.1186/1742-2094-
4-12.
110. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 
family determines the epithelial phenotype of cancer cells 
by targeting the E-cadherin repressors ZEB1 and ZEB2. 
Genes Dev. 2008; 22:894-907. doi: 10.1101/gad.1640608.
111. Liu S, Tetzlaff MT, Cui R, Xu X. miR-200c inhibits 
melanoma progression and drug resistance through down-
regulation of BMI-1. Am J Pathol. 2012; 181:1823-35. doi: 
10.1016/j.ajpath.2012.07.009. 
112. Liu S, Tetzlaff MT, Wang T, Yang R, Xie L, Zhang G, 
Krepler C, Xiao M, Beqiri M, Xu W, Karakousis G, 
Schuchter L, Amaravadi RK et al. miR-200c/Bmi1 axis and 
epithelial-mesenchymal transition contribute to acquired 
resistance to BRAF inhibitor treatment. Pigment Cell 
Melanoma Res. 2015; 28:431-41. doi: 10.1111/pcmr.12379. 
113. Noto A, De Vitis C, Roscilli G, Fattore L, Malpicci 
D, Marra E, Luberto L, D’Andrilli A, Coluccia P, 
Giovagnoli MR, Normanno N, Ruco L, Aurisicchio L et 
al. Combination therapy with anti-ErbB3 monoclonal 
antibodies and EGFR TKIs potently inhibits non-small cell 
lung cancer. Oncotarget. 2013; 4:1253-65. doi: 10.18632/
oncotarget.1141.
114. Hu B, Ying X, Wang J, Piriyapongsa J, Jordan IK, Sheng 
J, Yu F, Zhao P, Li Y, Wang H, Ng WL, Hu S, Wang X 
et al. Identification of a tumor-suppressive human-specific 
microRNA within the FHIT tumor-suppressor gene. Cancer 
Res. 2014; 74:2283-94. doi: 10.1158/0008-5472.CAN-13-
3279. 
115. Laganà A, Forte S, Giudice A, Arena MR, Puglisi PL, 
Giugno R, Pulvirenti A, Shasha D, Ferro A. miRò: a 
miRNA knowledge base. Database (Oxford). 2009; 
2009:bap008. doi: 10.1093/database/bap008.
116. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The 
microRNA.org resource: targets and expression. Nucleic 
Acids Res. 2008; 36(Database issue):D149-53. doi: 
10.1093/nar/gkm995.
117. Lu M, Breyssens H, Salter V, Zhong S, Hu Y, Baer C, 
Ratnayaka I, Sullivan A, Brown NR, Endicott J, Knapp S, 
Kessler BM, Middleton MR et al. Restoring p53 function in 
human melanoma cells by inhibiting MDM2 and cyclin B1/
CDK1-phosphorylated nuclear iASPP. Cancer Cell. 2013; 
23:618-33. doi: 10.1016/j.ccr.2013.03.013. 
118. Zhang T, Dutton-Regester K, Brown KM, Hayward NK. 
The genomic landscape of cutaneous melanoma. Pigment 
Cell Melanoma Res. 2016; 29:266-83. doi: 10.1111/
Oncotarget22278www.impactjournals.com/oncotarget
pcmr.12459. 
119. Muthiah M, Park IK, Cho CS. Nanoparticle-mediated 
delivery of therapeutic genes: focus on miRNA 
therapeutics. Expert Opin Drug Deliv. 2013; 10:1259-73. 
doi: 10.1517/17425247.2013.798640. 
120. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, 
Lotvall JO. Exosome-mediated transfer of mRNAs and 
microRNAs is a novel mechanism of genetic exchange 
between cells. Nat Cell Biol. 2007; 9:654-9. doi: 10.1038/
ncb1596.
121. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, 
Remaley AT. MicroRNAs are transported in plasma and 
delivered to recipient cells by high-density lipoproteins. Nat 
Cell Biol. 2011; 13:423-33. doi: 10.1038/ncb2210. 
122. Ono S, Oyama T, Lam S, Chong K, Foshag LJ, Hoon DS. 
A direct plasma assay of circulating microRNA-210 of 
hypoxia can identify early systemic metastasis recurrence 
in melanoma patients. Oncotarget. 2015; 6:7053-64. doi: 
10.18632/oncotarget.3142.
123. Margue C, Reinsbach S, Philippidou D, Beaume N, 
Walters C, Schneider JG, Nashan D, Behrmann I, Kreis S. 
Comparison of a healthy miRNome with melanoma patient 
miRNomes: are microRNAs suitable serum biomarkers 
for cancer? Oncotarget. 2015; 6:12110-27. doi: 10.18632/
oncotarget.3661.
124. Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical 
relevance of circulating cell-free microRNAs in cancer. 
Nat Rev Clin Oncol. 2014; 11:145-56. doi: 10.1038/
nrclinonc.2014.5. 
125. Mitchell PS1, Parkin RK, Kroh EM, Fritz BR, Wyman 
SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, 
O’Briant KC, Allen A, Lin DW, Urban N, Drescher CW et 
al. Circulating microRNAs as stable blood-based markers 
for cancer detection. Proc Natl Acad Sci U S A. 2008; 
105:10513-8. doi: 10.1073/pnas.0804549105. 
